Table I.
SARS-CoV-2 infection characteristics of patients treated with systemic therapies
| Characteristics | SARS-CoV-2 infection |
||||||
|---|---|---|---|---|---|---|---|
| Possible case,∗ n = 36 (%) | Probable case,† n = 16 (%) | PCR confirmed case,‡ n = 21 (%) | Hospitalized case, n = 13 (%) | ICU case, n = 1 (%) | Death case, n = 1 (%) | All cases, n = 73 (%) | |
| Sex | |||||||
| Male | 21 (58) | 11 (69) | 11 (52) | 10 (77) | 0 (0) | 1 (100) | 43 (59) |
| Female | 15 (42) | 5 (31) | 10 (48) | 3 (23) | 1 (100) | 0 (0) | 30 (41) |
| Age (y), median (p25-p75) | 51.3 (38.8-59.8) | 49.9 (32.7-54.6) | 54.8 (49.6-68.3) | 54.8 (51.5-68.3) | 51.2 (NA) | 79.5 (NA) | 51.8 (39.6-60.0) |
| Plaque psoriasis, yes | 35 (97) | 15 (94) | 19 (90) | 12 (92) | 1 (100) | 1 (100) | 69 (95) |
| Psoriatic arthritis, yes | 2 (6) | 2 (13) | 5 (24) | 4 (31) | 1 (100) | 0 (0) | 9 (12) |
| Treatment | |||||||
| Anti-TNF | 6 (16) | 5 (31) | 2 (10) | 1 (8) | 0 (0) | 0 (0) | 13 (18) |
| Classic systemics treatments | 3 (9) | 2 (12) | 4 (19) | 2 (15) | 0 (0) | 0 (0) | 9 (12) |
| Anti-IL-12/IL-23 | 9 (25) | 4 (25) | 3 (14) | 4 (31) | 0 (0) | 0 (0) | 16 (22) |
| Anti-IL17 | 6 (17) | 5 (32) | 2 (10) | 1 (8) | 0 (0) | 0 (0) | 13 (18) |
| Apremilast | 6 (17) | 0 (0) | 6 (29) | 2 (15) | 0 (0) | 1 (100) | 12 (16) |
| Fumarates | 1 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| Anti-IL-23p19 | 5 (14) | 0 (0) | 4 (19) | 3 (23) | 1 (100) | 0 (0) | 9 (12) |
| Changes in current treatment | |||||||
| No | 29 (81) | 12 (75) | 20 (95) | 12 (92) | 1 (100) | 1 (100) | 61 (84) |
| Preventive minimization | 3 (8) | 2 (13) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 5 (7) |
| Preventive suspension | 4 (11) | 2 (13) | 1 (5) | 1 (8) | 0 (0) | 0 (0) | 7 (10) |
| Hypertension, yes | 11 (31) | 3 (19) | 6 (29) | 5 (38) | 0 (0) | 1 (100) | 20 (27) |
| Diabetes mellitus, yes | 7 (19) | 2 (13) | 3 (14) | 5 (38) | 0 (0) | 0 (0) | 12 (16) |
| Cardiovascular disease, yes | 6 (17) | 2 (13) | 4 (19) | 4 (31) | 0 (0) | 1 (100) | 12 (16) |
| Respiratory tract disease, yes§ | 8 (22) | 4 (25) | 1 (5) | 3 (23) | 0 (0) | NA | 13 (18) |
| ARA II or ACE treatments, yes | 8 (22) | 3 (19) | 5 (24) | 4 (31) | 0 (0) | 1 (100) | 16 (22) |
| Relative hospitalized or death by COVID-19∗ | 3 (10) | 2 (17) | 2 (22) | 5 (100) | 1 (100) | NA | 7 (14) |
| Time since first symptom, median (p25-p75)∗ | 20.5 (12-26) | 23 (15-41) | 18 (13.5-30) | 23 (13-30) | 30 (NA) | 14 (NA) | 20 (13-30) |
| COVID-19 outcome | |||||||
| Mild symptoms or asymptomatic | 35 (97) | 12 (75) | 11 (52) | 0 (0) | 0 (0) | 0 (0) | 58 (79) |
| Hospitalization | 1 (3) | 4 (25) | 8 (38) | 13 (100) | 0 (0) | 0 (0) | 13 (18) |
| ICU admission or similar | 0 (0) | 0 (0) | 1 (5) | 0 (0) | 1 (100) | 0 (0) | 1 (1) |
| Death | 0 (0) | 0 (0) | 1 (5) | 0 (0) | 0 (0) | 1 (100) | 1 (1) |
ARA II, angiotensin II receptor antagonists; ACE, angiotensin-converting enzyme; IL, interleukin; TNF, tumor necrosis factor.
∗
Possible case: febrile respiratory infection with compatible symptoms.
†
Probable case: clinical criteria with an epidemiological link or any person meeting the diagnostic criteria.
‡
Confirmed case: laboratory confirmation of SARS-CoV-2, irrespective of clinical signs and symptoms.
§
Few missing data.